Bioblast Pharma Ltd. Stock Price and Value Analysis

Should you buy Bioblast Pharma Ltd. stock? (NasdaqCM:ORPN). Let's see how it does in our automated value investing analysis system.

  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company pays no dividend.

ORPN Free Cash Flow Trend

Hmm, we can't give any reliable projection for Bioblast Pharma Ltd.'s growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for ORPN
Free Cash Flow trendline for Bioblast Pharma Ltd.

Inside the ORPN Numbers

ORPN Price
(Bioblast Pharma Ltd. stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 67%

Is Bioblast Pharma Ltd. Stock on Sale?

Based on our analysis, we believe that you should not buy Bioblast Pharma Ltd. right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ORPN Stock?

Does Bioblast Pharma Ltd. have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.